DAWN
Day One Biopharmaceuticals
DAWN
DAWN
Delisted
DAWN was delisted on the 22nd of April, 2026.
140 hedge funds and large institutions have $941M invested in Day One Biopharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 60 increasing their positions, 23 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
15% more capital invested
Capital invested by funds: $818M → $941M (+$123M)
11% more funds holding
Funds holding: 126 → 140 (+14)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Holders
140
Holding in Top 10
2
Calls
$1.74M
Puts
$1.31M
Top Buyers
| 1 | +$22.2M | |
| 2 | +$17.1M | |
| 3 | +$16.6M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$15M |
Top Sellers
| 1 | -$13.2M | |
| 2 | -$5.38M | |
| 3 | -$3.13M | |
| 4 |
D.E. Shaw & Co
New York
|
-$2.76M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.36M |